Meeting Room: Room 331, Level 3, Suntec Singapore
|
Time
|
Programme
|
10:00 – 11:20
|
HBV Cure Overview
|
Chair and Moderator : Seng Gee Lim (Singapore)
|
10:00 – 10:10
|
Opening Lecture: How to Eradicate HBV?
|
Geoffrey Dusheiko, UK
|
10:10 – 10:20
|
State of the Action: HBV Cure Strategy from HBV Foundation
|
Robert Gish, HBV Foundation
|
10:20 – 10:40
|
International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) Progress Report 2019
|
Peter Revill, Australia
|
10:40 – 10:55
|
HBV Forum: Achievements to Date
|
Veronica Miller, USA
|
10:55 – 11:05
|
Insights for HBV Cure from HIV Cure Strategies
|
Jonathan Karn, USA
|
11:05– 11:20
|
Discussion Forum led by the Moderator
|
11:20 – 12:10
|
Models for HBV Infection
|
Chair and Moderator : Atefeh Khakpoor (Singapore)
|
11:20 – 11:35
|
Novel In-Vitro Models : An Overview
|
Peter Revill, Australia
|
11:35 – 11:50
|
Humanised Mouse Models: State of the Art
|
Qingfeng Chen, Singapore
|
11:50 – 12:10
|
Discussion Forum led by the Moderator
|
12:10 – 13:00
|
Lunch
|
13:00 – 14:30
|
Clinical & Translational Forum
|
Chair and Moderator: Peter Revill (Australia)
|
13:00 – 13:15
|
Insights into Host Genes in HBV Clearance
|
Martin Hibberd, Singapore
|
13:15 – 13:30
|
HBV Viral Integration : Implications for a HBV Cure
|
Stephan Urban, Germany
|
Invited Oral & Free Paper Presentations
|
13:30 – 13:45
|
Development of Novel Markers of Treatment Response
|
Gavin Cloherty, Abbott Diagnostics
|
13:45 – 13:55
|
Peginterferon Therapy in CHB Carriers, A Randomised Control Trial. Preliminary Results and Insights
|
Seng Gee Lim, Singapore
|
13:55 – 14:05
|
Understanding IFN Subtype: Harnessing the Power of IFN for HBV Cure
|
Zhenghong Yuan, China
|
14:05 – 14:15
|
HBV Surface Antigen Large And Middle Isoform Composition Do Not Correlate To Disease Stage
|
Gavin Cloherty, Abbott Laboratories
|
14:15 – 14:30
|
Discussion Forum led by the Moderator
|
14:30 – 16:25
|
Viral Transcription
|
Chair and Moderator: Stephen Locarnini (Australia)
|
14:30 – 14:45
|
cccDNA Update: Where Are We in 2019?
|
Haitao Guo, USA
|
14:45 – 15:00
|
State of the Art: CRISPR-CAS9 in Human Cells
|
Tan Meng How, Singapore
|
15:00 – 15:30
|
Debate: HBV cccDNA Management
|
· It is better to eliminate cccDNA: Massimo Levrero, France
|
· It is better to silence cccDNA: Haitao Guo, USA
|
Invited Oral & Free Paper Presentations
|
15:30 – 15:40
|
Using a modified HBV genome and insertional chromatin immunoprecipitation to screen for cccDNA-associated nuclear factors
|
Nur Khairiah Mohd-Ismail, Singapore
|
15:40 – 15:50
|
A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model
|
Lu Gao, Roche
|
15:50 – 16:00
|
Thiazolides in the treatment of chronic HBV: Can it be a cure
|
Jean-François Rossignol, Romark, L.C
|
16:00 – 16:25
|
Discussion Forum led by the Moderator
|
16:25 – 16:40
|
Tea Break
|
16:40 – 18:00
|
Capsid Inhibition
|
Chair and Moderator: Jorg Peterson (Germany)
|
16:40 – 16:55
|
Mechanism and Efficacy of Capsid Inhibitors
|
Stephen Locarnini, Australia
|
16:55 – 17:10
|
Biology of HBV Core Phosphorylation and Targets
|
Pei-Jer Chen, Taiwan
|
Invited Oral & Free Paper Presentations
|
17:10 – 17:20
|
RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients
|
Man-Fung Yuen, Hong Kong
|
17:20 – 17:30
|
Targeting a functional cure for HBV: learning from the clinical studies of the capsid assembly modulators JNJ-6379 and JNJ-0440
|
Oliver Lenz, Janssen Pharmaceutica
|
17:30 – 17:40
|
Proteome and Phosphosproteome profiling Of Hepatitis B Virus (HBV)-Infected Cells
|
Lim Zijie, Singapore
|
17:40 – 18:00
|
Discussion Forum led by the Moderator
|
End of Day 1
|
发表于 2019-6-3 22:21